文献速递神经免疫认知障碍与痴呆

多发性硬化灰质损伤与长期残疾、认知结局及生存的关联

Gray Matter Damage and Long-Term Disability, Cognitive Outcome, and Survival in Patients With Multiple Sclerosis.
PubMed 文献 · Neurology · 2026-07-21

结果显示基线灰质分数降低及灰质磁化转移率改变与长期残疾恶化、疾病阶段进展、MS相关死亡和认知下降相关,支持灰质MRI标志物的长期临床价值。

要点

  • 基线灰质分数降低与长期EDSS恶化和疾病阶段进展独立相关。
  • 基线灰质磁化转移率降低及12个月下降与MS相关死亡和认知下降相关。
  • 灰质MRI指标可能有助于识别长期不良结局高风险的多发性硬化患者。

核心结论

  • 在复发型多发性硬化中,脑灰质损伤与26年随访期间的残疾恶化、疾病阶段进展、死亡和认知下降呈一致关联。

主要发现

  • 随访期间79.5%患者出现EDSS恶化,72.6%进展至更严重疾病阶段,24.7%死于多发性硬化相关原因,有认知数据的43例中39.5%出现认知下降。
  • EDSS恶化与较低基线灰质分数(标准化β=-0.561)、升级至高疗效疾病修饰治疗(标准化β=0.059)、较低基线丘脑分数(标准化β=-0.115)、较低基线正常表现白质MTR直方图峰值高度(标准化β=-0.010)及12个月灰质MTR直方图峰值高度下降较大(标准化β=-0.115)相关(AUC=0.843,95%CI 0.744-0.941)。
  • 进展至更严重疾病阶段与12个月EDSS评分变化较大(标准化β=0.167)及较低基线灰质分数(标准化β=-0.151)相关(AUC=0.793,95%CI 0.670-0.916)。
  • 多发性硬化相关死亡与男性(标准化β=0.063)、较高基线EDSS评分(标准化β=0.182)、较低基线灰质分数(标准化β=-0.304)、较低基线灰质MTR直方图峰值高度(标准化β=-0.050)及12个月平均丘脑MTR下降较大(标准化β=-0.370)相关(AUC=0.887,95%CI 0.813-0.961)。
  • 认知下降与较大基线年龄(标准化β=0.197)、较低基线脑实质分数(标准化β=-0.039)及较低基线平均灰质MTR(标准化β=-0.376)相关(AUC=0.891,95%CI 0.788-0.994)。

临床怎么用

  • 临床可关注基线灰质分数和灰质MTR等MRI标志物,辅助评估多发性硬化患者长期残疾、死亡和认知下降风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Gray matter (GM) damage is a key determinant of clinical disability in multiple sclerosis (MS), but its relevance to very long-term outcomes remains insufficiently characterized. We assessed associations between baseline and 12-month MRI measures of GM and white matter (WM) damage and long-term outcomes in relapse-onset MS. METHODS: We conducted a prospective longitudinal single-center cohort study of relapse-onset MS patients enrolled between 1993 and 1998. Participants underwent clinical and 1.5T brain MRI assessments at baseline and after 12 months. MRI measures included T2-lesion and T1-lesion volumes, GM, WM, and thalamic volume fractions, magnetization transfer ratio (MTR) of GM, thalamus, normal-appearing WM, and WM lesions. Escalation to high-efficacy disease-modifying therapies (HE-DMTs) was recorded. Outcomes included Expanded Disability Status Scale (EDSS) worsening, evolution to a more severe disease stage, MS-related death, and cognitive deterioration. Associations were evaluated using LASSO-regularized logistic regression with internal bootstrap validation. RESULTS: Seventy-three relapse-onset MS patients (mean age = 33.0 years; female = 69.9%) were followed for a median of 25.9 years (interquartile range = 18.1-27.1; patients lost during follow-up = 11). EDSS worsening occurred in 79.5% of patients, 72.6% evolved to a more severe disease stage, 24.7% died from MS-related causes, and 39.5% of patients with cognitive data (17/43) experienced cognitive deterioration. EDSS worsening was associated with lower baseline GM fraction (GMF) (standardized-β = -0.561), escalation to HE-DMTs (standardized-β = 0.059), lower baseline thalamic fraction (standardized-β = -0.115), lower baseline normal-appearing WM MTR histogram peak height (standardized-β = -0.010), and greater 12-month decline in GM MTR histogram peak height (standardized-β = -0.115) (area under the curve [AUC] = 0.843, 95% CI 0.744-0.941). Evolution to a more severe disease stage was associated with higher 12-month EDSS score change (standardized-β = 0.167) and lower baseline GMF (standardized-β = -0.151) (AUC = 0.793, 95% CI 0.670-0.916). MS-related death was associated with male sex (standardized-β = 0.063), higher baseline EDSS score (standardized-β = 0.182), lower baseline GMF (standardized-β = -0.304), lower baseline GM MTR histogram peak height (standardized-β = -0.050), and greater 12-month decline in mean thalamic MTR (standardized-β = -0.370) (AUC = 0.887, 95% CI 0.813-0.961). Cognitive deterioration was associated with older baseline age (standardized-β = 0.197), lower baseline brain parenchymal fraction (standardized-β = -0.039), and lower baseline mean GM MTR (standardized-β = -0.376) (AUC = 0.891, 95% CI 0.788-0.994). DISCUSSION: Brain GM damage showed consistent associations with disability worsening and evolution, mortality, and cognitive deterioration over 26 years in relapse-onset MS, supporting the long-term clinical relevance of GM-focused MRI markers.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Preziosa P, Meani A, Tedone N, et al. Gray Matter Damage and Long-Term Disability, Cognitive Outcome, and Survival in Patients With Multiple Sclerosis. Neurology. 2026. PMID: 42479991. doi:10.1212/WNL.0000000000218310

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。